tiprankstipranks

Aardvark Therapeutics price target raised to $26 from $22 at BofA

BofA analyst Tim Anderson raised the firm’s price target on Aardvark Therapeutics (AARD) to $26 from $22 and keeps a Buy rating on the shares after Soleno Therapeutics (SLNO), a competitor to Aardvark, received FDA approval for treating hyperphagia associated with Prader-Willi syndrome in patients 4 and older under the brand name Vykat XR. The firm views the competitor’s news “favorably” for Aardvark and as partially de-risking for ARD101.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue